KALVISTA PHARMACEUTICALS INC

KALV14 Dec 2024
Healthcare
$8.61
-0.01 (-0.63%)
Lowest Today
$8.48
Highest Today
$8.91
Today’s Open
$8.61
Prev. Close
$8.75
52 Week High
$16.88
52 Week Low
$8.48
To Invest in KALVISTA PHARMACEUTICALS INC

KALVISTA PHARMACEUTICALS INC

Healthcare
KALV14 Dec 2024
-0.01 (-0.63%)
1M
3M
6M
1Y
5Y
Low
$8.48
Day’s Range
High
$8.91
8.48
52 Week Low
$8.48
52-Week Range
52 Week High
$16.88
8.48
1 Day
-
1 Week
-6.94%
1 month return
-11.07%
3 month return
-19%
6 month return
-27.91%
1 Year return
-17%
3 Years return
-33.67%
5 Years return
-47.78%
10 Years return
-
Institutional Holdings
VR Adviser, LLC
12.7
TANG CAPITAL MANAGEMENT LLC
8.78
Suvretta Capital Management, LLC
8.56
Vestal Point Capital LP
8.13
American Funds SMALLCAP World A
6.86
Capital World Investors
6.86
BlackRock Inc
5.98

Market Status

Fundamentals
Market Cap
449.21 mln
PB Ratio
3.23
PE Ratio
0
Enterprise Value
319.65 mln
Total Assets
235.4 mln
Volume

Company Financials

Fund house & investment objective

Company Information
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.
Organisation
KALVISTA PHARMACEUTICALS INC
Employees
150
Industry
Biotechnology
CEO
Mr. Benjamin L. Palleiko
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step